Superworth

ALX Oncology revenue ALXO

Sales by quarter and over the last twelve months, from 2019.

Last 12 months, to Dec 31, 2020
$1.2M
Latest quarter, Q4 FY20
$0
−100% on a year earlier
Fiscal year 2020
$1.2M
−75% on the year before

ALX Oncology's revenue was $1.2M over the twelve months to Dec 31, 2020, down 75% on a year earlier.

In its latest quarter, Q4 FY20, it was $0, down 100% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2020$1.2M−75%
FY2019$4.8Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q4 FY20$0−100%$1.2M
Q3 FY20$0−100%$2.4M
Q2 FY20$527K−59%$3.7M
Q1 FY20$655K−37%$4.4M
Q4 FY19$1.2Mn/a$4.8M
Q3 FY19$1.3Mn/an/a
Q2 FY19$1.3Mn/an/a
Q1 FY19$1Mn/an/a

Against its peers

Companies in Drug Manufacturers - General nearest ALX Oncology's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
ALXOALX Oncologyn/m
NATRNatures Sunshine Products$492M+7% a year
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
ARVNArvinas$316.7M−15% a year
ATNMActinium Pharmaceuticalsn/m
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
Peer median$316.7M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on ALX Oncology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.